AOB American Oriental Bioengineering, Inc.

China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) ("China Aoxing"), a pharmaceutical company specializing in research, development, manufacturing and marketing of narcotic and pain-management products, today announced that it received a new production license for Isosorbide Mononitrate Injection from the China State Food and Drug Administration ("SFDA") for treatment of angina pectoris, myocardial infarction, of chronic congestive heart failure, pulmonary hypertension and related coronary artery disease.

"Angina along with coronary artery disease is a leading health problem among people over the age of 50. Approximately 30 million people in China suffer from Angina. Isosorbide Mononitrate is an effective intravenous injection drug in hospitals to treat this public heath problem," said Juan Yue Han, Chairman and the CEO of China Aoxing. "We are very excited to have another drug approval in year 2009. This approval further underscores China Aoxing's long-term commitment to developing high quality hospital care therapies. We are looking forward to launching this product in the second half of 2009."

About Angina Pectoris

Angina Pectoris is a term for chest pain caused by an inadequate supply of blood and oxygen to the heart. It is often associated with the narrowed arteries found in coronary artery disease (CAD). This narrowing is due to atherosclerosis. It is common in people over the age of 50. Sometimes it occurs in younger people. It is more common in men than women. With angina, the affected patient's heart may get sufficient blood for daily activities, but the arteries may not be able to respond appropriately to increased demands for oxygen during exercise, times of emotional or physical stress, and with extremes of temperature.

About Isosorbide Mononitrate Injection

Isosorbide mononitrate is a metabolite of isosorbide dinitrate, a vasodilatory agent which is converted to nitric oxide (NO), activates the enzyme guanylate cyclase, thereby stimulating the synthesis of cyclic guanosine 3',5'-monophosphate (cGMP) and this then activates a series of protein kinase dependent phosphorylations in the smooth muscle cells, eventually resulting in the dephosphorylation of the myosin light chain and the subsequent release of calcium ions thereby relaxing the smooth muscle cells and producing vasodilation. It is used in the treatment of angina pectoris, myocardial infarction, of chronic congestive heart failure, pulmonary hypertension and related coronary artery disease.

About China Aoxing Pharmaceutical Company, Inc.

China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) is a pharmaceutical company located in China specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. It has a strategic alliance with American Oriental Bioengineering, Inc. (NYSE: AOB) to develop and market various narcotic drugs in China. Headquartered in Shijiazhuang City, the pharmaceutical capital of China, outside of Beijing, China Aoxing has China's largest and the most advanced manufacturing facility for highly regulated narcotic medicines, addressing a very under-served and fast-growing market in China. Its facility is one of the few GMP facilities licensed for narcotics medicines. The Company is working closely with the Chinese government and SFDA to assure the strictly regulated availability to medical professionals of its narcotic drugs and pain medicines throughout China.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-KSB for the year ended June 30, 2008, may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Contact: Wei Zhang Investor Relations China Aoxing Pharmaceutical Company, Inc Email: chinaaoxing@gmail.com Telephone: 646 - 512 - 5662